- Icelandic biotech Alvotech ( NASDAQ: ALVO ) on Thursday said it had started a confirmatory clinical trial for its AVT06 biosimilar candidate to Regeneron's ( REGN ) blockbuster eye injection Eylea.
- The objective of the study is to compare AVT06 and Eylea in terms of efficacy, safety, and immunogenicity in adult patients with wet age-related macular degeneration, a chronic eye disease.
- The confirmatory study, called ALVOEYE, is expected to enroll about 444 participants globally.
- The main goal of the study will be the change in visual impairment in the participants at week 8 of the trial.
- Regeneron's Eylea brought in U.S. net sales of $1.52B in Q1 2022 , a 13% Y/Y growth.
- ALVO stock closed -2.8% at $8.50 on Wednesday.
For further details see:
Alvotech starts confirmatory study for its AVT06 biosimilar to Regeneron's Eylea